BCL2L2-PABPN1 as a Radioligand Therapy Target
BCL2L2-PABPN1, BCL2L2-PABPN1 readthrough, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, BCL2L2-PABPN1 staining is highest in skin cancer (100% of samples positive), colorectal cancer (100% of samples positive) and head and neck cancer (100% of samples positive). Clinical status: Clinical-stage (up to phase 3, any modality).
Is BCL2L2-PABPN1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in skin cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 3, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
BCL2L2-PABPN1 expression in cancer
Protein expression of BCL2L2-PABPN1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Skin Cancer | 1.00 | High | 100% |
| Colorectal Cancer | 1.00 | High | 100% |
| Head and Neck Cancer | 1.00 | High | 100% |
| Ovarian Cancer | 1.00 | High | 100% |
| Breast Cancer | 1.00 | High | 100% |
| Thyroid Cancer | 1.00 | High | 100% |
| Neuroendocrine Tumors | 1.00 | High | 100% |
| Cervical Cancer | 1.00 | High | 100% |
| Prostate Cancer | 1.00 | High | 100% |
| Gastric Cancer | 1.00 | High | 100% |
| Lung Cancer | 0.97 | High | 100% |
| Melanoma | 0.97 | High | 100% |
| Endometrial Cancer | 0.89 | High | 100% |
| Pancreatic Cancer | 0.86 | High | 100% |
| Bladder Cancer | 0.81 | High | 100% |
| Glioma | 0.81 | High | 92% |
| Testicular Cancer | 0.76 | High | 100% |
| Lymphoma | 0.69 | High | 92% |
| Liver Cancer | 0.50 | Medium | 67% |
| Kidney Cancer | 0.48 | Medium | 82% |
Is BCL2L2-PABPN1 internalized?
Nuclens has not yet extracted internalization evidence for BCL2L2-PABPN1. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
BCL2L2-PABPN1 clinical trials
Clinical-stage (up to phase 3, any modality). Nuclens hasn't indexed trials for BCL2L2-PABPN1 yet. Search ClinicalTrials.gov for BCL2L2-PABPN1 trials.
BCL2L2-PABPN1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See BCL2L2-PABPN1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
Related skin cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · B7-H3 (CD276) · SSTR2 · ITGB6 · HER2 (ERBB2) · ITGAV
See all radioligand therapy targets in skin cancer.
See how BCL2L2-PABPN1 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.